Evidence map›Paper›PMID 27896668›Full record

ArticleDrug delivery and translational research2017

Target-specific delivery of siRNA into hepatoma cells' cytoplasm by bifunctional carrier peptide.

Xiaoxuan Liu, Lin Zhu, Jingjing Ma, Xinxiao Qiao, Dunwan Zhu, Lanxia Liu, Xigang Leng

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xiaoxuan LiuLab of Bioengineering, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laboratory of Biomedical Materials, No.236, Baidi Road, Nankai District, Tianjin, 300192, People's Republic of China.
Lin ZhuLab of Bioengineering, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laboratory of Biomedical Materials, No.236, Baidi Road, Nankai District, Tianjin, 300192, People's Republic of China.
Jingjing MaLab of Bioengineering, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laboratory of Biomedical Materials, No.236, Baidi Road, Nankai District, Tianjin, 300192, People's Republic of China.
Xinxiao QiaoLab of Bioengineering, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laboratory of Biomedical Materials, No.236, Baidi Road, Nankai District, Tianjin, 300192, People's Republic of China.
Dunwan ZhuLab of Bioengineering, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laboratory of Biomedical Materials, No.236, Baidi Road, Nankai District, Tianjin, 300192, People's Republic of China.
Lanxia LiuLab of Bioengineering, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laboratory of Biomedical Materials, No.236, Baidi Road, Nankai District, Tianjin, 300192, People's Republic of China. liulanxiabme@163.com.
Xigang LengLab of Bioengineering, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laboratory of Biomedical Materials, No.236, Baidi Road, Nankai District, Tianjin, 300192, People's Republic of China. lengxigangbme@163.com.
Chinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA interference (RNAi) is among the most potential approach for the therapy of hepatocellular carcinoma and the major barrier hindering siRNA therapeutics is the low efficiency of delivery to the desired cells. The current study aimed at developing a novel peptide for more efficient hepatoma targeted siRNA delivery, by combining luteinizing hormone-releasing hormone with hepatoma targeting specificity and MPG

Indexed as

Carcinoma, HepatocellularCell LineCell SurvivalCytoplasmDNA-Binding ProteinsGlyceraldehyde 3-Phosphate Dehydrogenase (NADP+)Gonadotropin-Releasing HormoneHep G2 CellsHumansLiver NeoplasmsRNA, Small InterferingDNA-Binding ProteinsGlyceraldehyde 3-Phosphate Dehydrogenase (NADP+)Gonadotropin-Releasing HormoneMPG peptideRNA, Small InterferingCancer therapyHepatomaLHRH-MPG△NLSsiRNA delivery

Identifiers

PMID27896668
OpenAlexW2558176372

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.